Total Funding
56
Total FundingGrant raised
Growth Score in past quarter
pts
Heat Score 56 in past quarter
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
47367
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Acquired by 
Recursion Pharmaceuticals
- Andrew Hopkins: Co-Founder and CEO
- Adrian Schreyer: Chief Technology OfficerPast Role: Exscientia, Head of Molecular Informatics
About the Company
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the
pharmaceutical industry.